OBJECTIVE: Although many survivors continue to worry about cancer years after completing treatment, little is known about factors associated with cancer worry. This study examined associations between breast cancer worry and demographic and clinical variables, as well as fatigue, symptom burden, and risk perception in a sample of breast cancer survivors 3 years post-adjuvant treatment. We hypothesized that after controlling for demographic and treatment factors, a significant proportion of variance in cancer worry would be explained by greater fatigue severity, more symptom burden, and greater perceived risk of recurrence. METHODS: Stage 0-II breast cancer patients (N = 202) completed measures of risk perception, cancer worry (modified Lerman's Cancer Worry Scale), symptom burden (Memorial Symptom Assessment Scale), and fatigue severity (Fatigue Symptom Inventory) 3 years after completing adjuvant treatment. Multiple regression analyses were used to determine the proportion of variance in cancer worry accounted for by fatigue, symptom burden, and risk perception after controlling for demographic and clinical variables. RESULTS: Age, fatigue, symptom burden, and risk perception each explained a significant proportion of variance in cancer worry (p < 0.05). Fatigue, symptom burden, and risk perception together accounted for 27% of the variance in cancer worry after controlling for demographic and clinical factors (p < 0.01). CONCLUSIONS: The hypothesis was supported that fatigue, symptom burden, and risk perception are associated with cancer worry among breast cancer survivors. It is possible that lingering fatigue and other symptoms may remind breast cancer survivors of their disease.
OBJECTIVE: Although many survivors continue to worry about cancer years after completing treatment, little is known about factors associated with cancer worry. This study examined associations between breast cancer worry and demographic and clinical variables, as well as fatigue, symptom burden, and risk perception in a sample of breast cancer survivors 3 years post-adjuvant treatment. We hypothesized that after controlling for demographic and treatment factors, a significant proportion of variance in cancer worry would be explained by greater fatigue severity, more symptom burden, and greater perceived risk of recurrence. METHODS: Stage 0-II breast cancerpatients (N = 202) completed measures of risk perception, cancer worry (modified Lerman's Cancer Worry Scale), symptom burden (Memorial Symptom Assessment Scale), and fatigue severity (Fatigue Symptom Inventory) 3 years after completing adjuvant treatment. Multiple regression analyses were used to determine the proportion of variance in cancer worry accounted for by fatigue, symptom burden, and risk perception after controlling for demographic and clinical variables. RESULTS: Age, fatigue, symptom burden, and risk perception each explained a significant proportion of variance in cancer worry (p < 0.05). Fatigue, symptom burden, and risk perception together accounted for 27% of the variance in cancer worry after controlling for demographic and clinical factors (p < 0.01). CONCLUSIONS: The hypothesis was supported that fatigue, symptom burden, and risk perception are associated with cancer worry among breast cancer survivors. It is possible that lingering fatigue and other symptoms may remind breast cancer survivors of their disease.
Authors: Annette L Stanton; Patricia A Ganz; Julia H Rowland; Beth E Meyerowitz; Janice L Krupnick; Sharon R Sears Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg Journal: Breast Cancer Res Treat Date: 2000-12 Impact factor: 4.872
Authors: Martine M Goedendorp; Michael A Andrykowski; Kristine A Donovan; Heather S Jim; Kristin M Phillips; Brent J Small; Christine Laronga; Paul B Jacobsen Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart Journal: Thyroid Date: 2019-07-25 Impact factor: 6.568
Authors: Donna M Posluszny; Mary Amanda Dew; Ellen Beckjord; Dana H Bovbjerg; John E Schmidt; Carissa A Low; Amy Lowery; Stephanie A Nutt; Sarah R Arvey; Ruth Rechis Journal: J Health Psychol Date: 2015-04-06
Authors: Salene M W Jones; Rebecca Ziebell; Rod Walker; Larissa Nekhlyudov; Borsika A Rabin; Stephanie Nutt; Monica Fujii; Jessica Chubak Journal: Support Care Cancer Date: 2016-12-15 Impact factor: 3.603
Authors: Michelle Y Martin; Mona N Fouad; Robert A Oster; Deborah Schrag; Julie Urmie; Sara Sanders; Maria Pisu Journal: Support Care Cancer Date: 2013-09-14 Impact factor: 3.603
Authors: Sherrie Khadanga; Susan G Lakoski; Vicki Hart; Brian L Sprague; Yi Ba; John M Hampton; Stephen T Higgins; Philip A Ades; Polly A Newcomb; Amy Trentham-Dietz Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-11-06 Impact factor: 4.254